Neuroprotective efficacy of ebselen, an anti-oxidant with anti-inflammatory actions, in a rodent model of permanent middle cerebral artery occlusion
- PMID: 9401794
- PMCID: PMC1565026
- DOI: 10.1038/sj.bjp.0701426
Neuroprotective efficacy of ebselen, an anti-oxidant with anti-inflammatory actions, in a rodent model of permanent middle cerebral artery occlusion
Abstract
1. The aim of this study was to investigate whether delayed treatment with the anti-oxidant and anti-inflammatory agent ebselen reduces the volume of infarction in a rodent model of permanent focal cerebral ischaemia. 2. Ebselen (10 or 30 mg kg-1) or vehicle was administered by gavage 30 min and 12 h after the induction of cerebral ischaemia by permanent occlusion of the left middle cerebral artery (MCA). Animals were killed 24 h following MCA occlusion, and the volumes of ischaemic damage in the ebselen and control groups were evaluated by quantitative histopathology. 3. Ebselen was quickly absorbed following oral (gavage) administration and reached peak levels in the plasma by 1 h post-administration (plasma selenium level of 0.68 +/- 0.04 and 0.84 +/- 0.1 microgram ml-1 for 10 and 30 mg kg-1, respectively, compared to control level of 0.51 +/- 0.02 microgram kg-1). 4. Treatment with the lower dose of ebselen (10 mg kg-1) significantly (P < 0.01) reduced the volume of infarction in the cerebral hemisphere and cerebral cortex (by 31.8% and 36.7%, respectively compared with the placebo group). 5. The neuroprotective efficacy of the higher dose ebselen (30 mg kg-1) was less than that of the lower dose ebselen (10 mg kg-1). The volume of ischaemic damage in the cerebral hemisphere was reduced by 23.7% (P < 0.02), and cerebral cortex by 27.5% (P < 0.01). 6. Both doses of ebselen (10, 30 mg kg-1) had no therapeutic efficacy on the caudate nucleus, where ischaemia was most severe, in this model. 7. Free radical-mediated injury is normally associated with reperfusion of ischaemic tissue. The present results suggest that oxidative injury is also a significant contributor to brain damage in models of maintained (permanent) ischaemia and that ebselen is effective in attenuating this free radical-induced damage.
Similar articles
-
Free radical trapping as a therapeutic approach to neuroprotection in stroke: experimental and clinical studies with NXY-059 and free radical scavengers.Curr Drug Targets CNS Neurol Disord. 2005 Apr;4(2):109-18. doi: 10.2174/1568007053544156. Curr Drug Targets CNS Neurol Disord. 2005. PMID: 15857295 Review.
-
Single-dose ebselen does not afford sustained neuroprotection to rats subjected to severe focal cerebral ischemia.Eur J Pharmacol. 2004 Jul 8;495(1):55-62. doi: 10.1016/j.ejphar.2004.05.024. Eur J Pharmacol. 2004. PMID: 15219820
-
Ebselen, a seleno-organic antioxidant, is neuroprotective after embolic strokes in rabbits: synergism with low-dose tissue plasminogen activator.Stroke. 2003 Aug;34(8):2013-8. doi: 10.1161/01.STR.0000081223.74129.04. Epub 2003 Jul 10. Stroke. 2003. PMID: 12855833
-
Ebselen: prospective therapy for cerebral ischaemia.Expert Opin Investig Drugs. 2000 Mar;9(3):607-19. doi: 10.1517/13543784.9.3.607. Expert Opin Investig Drugs. 2000. PMID: 11060699 Review.
-
The neuroprotective efficacy of ebselen (a glutathione peroxidase mimic) on brain damage induced by transient focal cerebral ischaemia in the rat.Neurosci Lett. 1995 Feb 6;185(1):65-9. doi: 10.1016/0304-3940(94)11226-9. Neurosci Lett. 1995. PMID: 7731557
Cited by
-
Should ebselen be considered for the treatment of mercury intoxication? A minireview.Toxicol Mech Methods. 2024 Jan;34(1):1-12. doi: 10.1080/15376516.2023.2258958. Epub 2024 Jan 1. Toxicol Mech Methods. 2024. PMID: 37731353 Free PMC article. Review.
-
Oxidative Stress in Ischemia/Reperfusion Injuries following Acute Ischemic Stroke.Biomedicines. 2022 Mar 1;10(3):574. doi: 10.3390/biomedicines10030574. Biomedicines. 2022. PMID: 35327376 Free PMC article. Review.
-
Ebselen reduces cigarette smoke-induced endothelial dysfunction in mice.Br J Pharmacol. 2021 Apr;178(8):1805-1818. doi: 10.1111/bph.15400. Epub 2021 Feb 27. Br J Pharmacol. 2021. PMID: 33523477 Free PMC article.
-
Novel Selenium-based compounds with therapeutic potential for SOD1-linked amyotrophic lateral sclerosis.EBioMedicine. 2020 Sep;59:102980. doi: 10.1016/j.ebiom.2020.102980. Epub 2020 Aug 30. EBioMedicine. 2020. PMID: 32862101 Free PMC article.
-
Ebselen as template for stabilization of A4V mutant dimer for motor neuron disease therapy.Commun Biol. 2020 Mar 5;3(1):97. doi: 10.1038/s42003-020-0826-3. Commun Biol. 2020. PMID: 32139772 Free PMC article.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical